FoxP3+ CD4+ T cells in systemic autoimmune diseases: The delicate balance between true regulatory T cells and effector Th-17 cells

Rheumatology

Volumn 50, Issue 4, 2011, Pages 646-656

  Abdulahad, Wayel H ^a   Boots, Annemieke M H ^a   Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Regulatory T cells; Systemic autoimmune diseases; T cells; T helper 17 cells

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CELL ISOLATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE COUNT; MICE; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TISSUE THERAPY;

EID: 79952787680     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq328     Document Type: Review

References (113)

1. + T cell subset that inhibits this autoimmune potential. J Exp Med 1993;177: 627-36.
2. Danke NA, Koelle DM, Yee C, Beheray S, Kwok WW. Autoreactive T cells in healthy individuals. J Immunol 2004;172:5967-72.
3. Gershon RK, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970;18:723-37.
4. Gershon RK, Kondo K. Infectious immunological tolerance. Immunology 1971;21:903-14.
5. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64.
6. +CD25 high regulatory cells in human peripheral blood. J Immunol 2001;167:1245-53.
7. + regulatory T cells in autoimmune diseases. Nat Clin Pract Rheumatol 2007;3:619-26.
8. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999; 162:5317-26.
9. Bensinger SJ, Bandeira A, Jordan MS, Caton AJ, Laufer TM. Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4(+)25(+) immunoregulatory T cells. J Exp Med 2001; 194:427-38.
10. + regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nat Immunol 2007;8:351-8.
11. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994;265:1237-40.
12. Sundstedt A, O'Neill EJ, Nicolson KS, Wraith DC. Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J Immunol 2003;170:1240-8.
13. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-42.
14. + regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007; 204:1757-64.
15. Sun CM, Hall JA, Blank RB et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 2007;204: 1775-85.
16. + T cells expressing the FoxP3 transcription factor. Immunity 2009; 30:899-911.
17. + regulatory T cells. Nat Immunol 2003;4:330-6.
18. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61.
19. Brunkow ME, Jeffery EW, Hjerrild KA et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001;27:68-73.
20. Chatila TA, Blaeser F, Ho N et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000;106:R75-81.
21. Wildin RS, Ramsdell F, Peake J et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001;27:18-20.
22. Bennett CL, Christie J, Ramsdell F et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001;27:20-1.
23. + T cells. Eur J Immunol 2007;37: 129-38.
24. + regulatory T cells. J Immunol 2004;172: 5986-93.
25. Takahashi T, Tagami T, Yamazaki S et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyteassociated antigen 4. J Exp Med 2000;192:303-10.
26. Huang CT, Workman CJ, Flies D et al. Role of LAG-3 in regulatory T cells. Immunity 2004;21:503-13.
27. McHugh RS, Whitters MJ, Piccirillo CA et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002;16: 311-23.
28. Szanya V, Ermann J, Taylor C, Holness C, Fathman CG. The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J Immunol 2002;169:2461-5.
29. + as well as CD25-regulatory T cells. Proc Natl Acad Sci USA 2002;99:13031-6.
30. Iellem A, Mariani M, Lang R et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 2001;194:847-53.
31. Bruder D, Probst-Kepper M, Westendorf AM et al. Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol 2004;34:623-30.
32. + T reg cells. J Exp Med 2006;203:1701-11.
33. Seddiki N, Santner-Nanan B, Martinson J et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:1693-700.
34. Yamaguchi T, Hirota K, Nagahama K et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 2007;27:145-59.
35. Mandapathil M, Lang S, Gorelik E, Whiteside TL. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods 2009;346:55-63.
36. + regulatory T cells allows for their purification from expansion cultures. Blood 2009;113: 5125-33.
37. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188: 287-96.
38. + regulatory T cells. J Immunol 2005;175:4180-3.
39. + regulatory T cell activity in both humans and mice. J Immunol 2004; 172:834-42.
40. Suri-Payer E, Cantor H. Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4(+)CD25(+) T cells. J Autoimmun 2001;16:115-23.
41. +) TH1-like responses. J Clin Invest 1996;98:1010-20.
42. + T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 2001;166:3008-18.
43. + regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002;168:1080-6.
44. Christ M, McCartney-Francis NL, Kulkarni AB et al. Immune dysregulation in TGF-beta 1-deficient mice. J Immunol 1994;153:1936-46.
45. Letterio JJ. Murine models define the role of TGF-beta as a master regulator of immune cell function. Cytokine Growth Factor Rev 2000;11:81-7.
46. Josien R, Douillard P, Guillot C et al. A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance. J Clin Invest 1998; 102:1920-6.
47. Collison LW, Workman CJ, Kuo TT et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450:566-9.
48. Niedbala W, Wei XQ, Cai B et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007;37:3021-9.
49. Collison LW, Pillai MR, Chaturvedi V, Vignali DA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol 2009;182:6121-8.
50. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004;21:589-601.
51. + regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005;174:1783-6.
52. + T cells selectively kill B lymphocytes. Blood 2006;107:3925-32.
53. Fallarino F, Grohmann U, You S et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006;176:6752-61.
54. Liang B, Workman C, Lee J et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 2008;180:5916-26.
55. Deaglio S, Dwyer KM, Gao W et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204:1257-65.
56. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110:1225-32.
57. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J Immunol 2006;177:6780-6.
58. Cua DJ, Sherlock J, Chen Y et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421:744-8.
59. Murphy CA, Langrish CL, Chen Y et al. Divergent proand antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951-7.
60. Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8.
61. Du J, Huang C, Zhou B, Ziegler SF. Isoform-specific inhibition of ROR alpha-mediated transcriptional activation by human FOXP3. J Immunol 2008;180:4785-92.
62. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008;112:2340-52.
63. + Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc Natl Acad Sci USA 2009;106:8635-40.
64. Voo KS, Wang YH, Santori FR et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA 2009;106:4793-8.
65. Beriou G, Costantino CM, Ashley CW et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009;113:4240-9.
66. Deknuydt F, Bioley G, Valmori D, Ayyoub M. IL-1beta and IL-2 convert human Treg into T(H)17 cells. Clin Immunol 2009;131:298-307.
67. Lee WW, Kang SW, Choi J et al. Regulating human Th17 cells via differential expression of IL-1 receptor. Blood 2010;115:530-40.
68. Harris KM, Fasano A, Mann DL. Monocytes differentiated with IL-15 support Th17 and Th1 responses to wheat gliadin: implications for celiac disease. Clin Immunol 2010; 135:430-9.
69. Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 2003; 170:2106-12.
70. Hayashi T, Hasegawa K, Adachi C. Elimination of CD4(+)CD25(+) T cell accelerates the development of glomerulonephritis during the preactive phase in autoimmune-prone female NZB x NZW F mice. Int J Exp Pathol 2005;86:289-96.
71. Hsu WT, Suen JL, Chiang BL. The role of CD4CD25 T cells in autoantibody production in murine lupus. Clin Exp Immunol 2006;145:513-9.
72. + regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. Immunology 2006; 117:280-6.
73. Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003;21:273-6.
74. + T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 2004;59: 198-202.
75. Miyara M, Amoura Z, Parizot C et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005;175:8392-400.
76. Suen JL, Li HT, Jong YJ, Chiang BL, Yen JH. Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus. Immunology 2009;127:196-205.
77. +CD25 high T cells in patients with new-onset systemic lupus erythematosus. Clin Exp Immunol 2008;153:182-7.
78. +. J Immunol 2009;182:1689-95.
79. Alvarado-Sanchez B, Hernandez-Castro B, Portales-Perez D et al. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2006; 27:110-8.
80. +CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178:2579-88.
81. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008;127:385-93.
82. Baranda L, de la FH, Layseca-Espinosa E et al. IL-15 and IL-15R in leucocytes from patients with systemic lupus erythematosus. Rheumatology 2005;44: 1507-13.
83. Aringer M, Stummvoll GH, Steiner G et al. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology 2001;40:876-81.
84. Park YB, Kim DS, Lee WK, Suh CH, Lee SK. Elevated serum interleukin-15 levels in systemic lupus erythematosus. Yonsei Med J 1999;40:343-8.
85. Zhao XF, Pan HF, Yuan H et al. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 2010;37:81-5.
86. Shah K, Lee WW, Lee SH et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther 2010;12:R53.
87. + T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 2003;33:215-23.
88. Ehrenstein MR, Evans JG, Singh A et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004;200: 277-85.
89. + regulatory T cell-mediated suppression in rheumatoid arthritis. Arthritis Rheum 2007;56:732-42.
90. Gonzalez-Alvaro I, Ortiz AM, Garcia-Vicuna R, Balsa A, Pascual-Salcedo D, Laffon A. Increased serum levels of interleukin-15 in rheumatoid arthritis with long-term disease. Clin Exp Rheumatol 2003;21:639-42.
91. Thurkow EW, van der Heijden IM, Breedveld FC et al. Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J Pathol 1997;181:444-50.
92. Ziolkowska M, Koc A, Luszczykiewicz G et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000;164:2832-8.
93. Shahrara S, Huang Q, Mandelin AM, Pope RM. TH-17 cells in rheumatoid arthritis. Arthritis Res Ther 2008;10: R93.
94. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009;60:1647-56.
95. van der Woude FJ, Rasmussen N, Lobatto S et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985;1:425-9.
96. Kallenberg CG, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2006;2:661-70.
97. Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CG. CD4-positive effector memory T cells participate in disease expression in ANCA-associated vasculitis. Ann N Y Acad Sci 2007;1107:22-31.
98. Abdulahad WH, Stegeman CA, Kallenberg CG. Review article: the role of CD4(+) T cells in ANCA-associated systemic vasculitis. Nephrology 2009;14:26-32.
99. Berden AE, Kallenberg CG, Savage CO et al. Cellular immunity in Wegener's granulomatosis: characterizing T lymphocytes. Arthritis Rheum 2009;60:1578-87.
100. + T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum 2007;56:2080-91.
101. Nogueira E, Hamour S, Sawant D et al. Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2010;25:2209-17.
102. + effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener's granulomatosis. Clin Immunol 2008;127:144-50.
103. Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CG. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum 2008;58:2196-205.
104. Fox RI. Sjogren's syndrome. Lancet 2005;366:321-31.
105. Gottenberg JE, Lavie F, Abbed K et al. CD4 CD25high regulatory T cells are not impaired in patients with primary Sjogren's syndrome. J Autoimmun 2005;24: 235-42.
106. Li X, Li X, Qian L et al. T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sjogren's syndrome. J Rheumatol 2007;34: 2438-45.
107. +bright T cells in peripheral blood of patients with primary Sjogren's syndrome. Lupus 2008;17:34-9.
108. + T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol 2008;173: 1389-96.
109. Reksten TR, Jonsson MV, Szyszko EA, Brun JG, Jonsson R, Brokstad KA. Cytokine and autoantibody profiling related to histopathological features in primary Sjogren's syndrome. Rheumatology 2009;48: 1102-6.
110. Nguyen CQ, Hu MH, Li Y, Stewart C, Peck AB. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome: findings in humans and mice. Arthritis Rheum 2008;58:734-43.
111. Sakai A, Sugawara Y, Kuroishi T, Sasano T, Sugawara S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjogren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 2008;181: 2898-906.
112. Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM. Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis. Am J Pathol 2009;175:1167-77.
113. + Treg free of contaminating effector cells. Blood 2009;113: 827-36.